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BACKGROUND: Lignans – oestrogenic substances present in various foods – are associated with postmenopausal breast cancer risk,
but not much is known regarding their effects on survival.
METHODS: In a follow-up study of 2653 postmenopausal breast cancer patients diagnosed between 2001 and 2005, vital status and
causes of death were verified through end of 2009. Hazard ratios (HRs) and 95% confidence intervals (CIs) for estimated
enterolignans, lignan-rich foods, and dietary fibre in relation to overall survival (OS) and breast cancer-specific survival (BCSS) were
assessed using Cox proportional hazards models stratified by age at diagnosis and adjusted for prognostic/confounding factors.
RESULTS: Median follow-up time was 6.4 years, and 321 women died, 235 with breast cancer. High estimated enterolactone and
enterodiol levels were associated with significantly lower overall mortality (highest quintile, HR¼ 0.60, 95% CI¼ 0.40–0.89,
PTrend¼ 0.02 and HR¼ 0.63, 95% CI¼ 0.42–0.95, PTrend¼ 0.02, respectively). Fibre intake was also associated with a significantly
lower overall mortality. Differentiated by median fibre intake, associations with estimated enterolignans were still evident at low but
not high fibre intake. There was no effect modification by oestrogen receptor status and menopausal hormone therapy.
CONCLUSION: Postmenopausal breast cancer patients with high estimated enterolignans may have a better survival.
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Lignans are biphenolic compounds in plant foods with a structure
similar to oestrogens. They are the major source of phyto-
oestrogens in Western populations and are primarily present in
fibre-rich foods (such as seeds, grains, vegetables, and fruits)
(Adlercreutz, 2007; Sonestedt and Wirfält, 2010). In the human gut,
plant lignans are converted by intestinal bacteria to the
enterolignans, enterolactone and enterodiol, which are bioactive
and are subsequently absorbed (Adlercreutz, 2007).
There are several mechanisms by which enterolignans may
protect against cancer. They were shown to have weak oestrogenic
activity and may bind to oestrogen receptors (ERs) (Mueller et al,
2004; Penttinen et al, 2007). Moreover, they may exert effects via
oestrogen receptor-independent mechanisms, such as inhibition of
tumour growth and angiogenesis, as well as stimulation of
apoptosis and of sex hormone-binding globulin production
(SHBG) (Adlercreutz et al, 1987; Power et al, 2006; Adlercreutz,
2007; Mense et al, 2008; Saarinen et al, 2008, 2010).
Lignans have been associated with postmenopausal breast
cancer risk; however, the results were inconsistent. Two recent
meta-analyses found lignans to be associated with a small risk
reduction only in postmenopausal but not in premenopausal
women based on studies in Eastern and Western countries
(Velentzis et al, 2009; Buck et al, 2010).
There is limited epidemiological evidence on the potential
effects of lignans with respect to breast cancer prognosis. Two
studies, conducted in the United States, assessed the association of
dietary plant lignans with survival in postmenopausal breast
cancer patients (Fink et al, 2007; McCann et al, 2009). One study
reported that a higher dietary lignan intake was associated with a
better prognosis (McCann et al, 2009), whereas the other found no
association (Fink et al, 2007). Neither study examined the
association of estimated enterolignans with survival.
Dietary fibre and a diet rich in fibre has been (inconsistently)
associated with a better survival after breast cancer (Holmes et al,
1999; Kroenke et al, 2005; Kellen et al, 2009). As lignans originate
partly from fibre complex in foods, it is still unclear whether
associations observed with fibre-rich foods are attributed to fibre
or enterolignans or both.
Thus, we investigated the association of estimated amounts of
enterolignans (enterolactone and enterodiol), dietary intake of
lignan-rich foods (seeds, bread, vegetables, and fruit), and dietary
fibre intake with overall and breast cancer-specific survival (BCSS)
in a large German cohort of postmenopausal breast cancer
patients. Furthermore, we examined whether this association is
modified by hormone receptor status of the tumours and
menopausal hormone therapy use at diagnosis.
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Our study population comprised breast cancer patients aged
50–74 years who participated in a population-based case–control
study carried out in two German study regions (Hamburg and
Rhein-Neckar-Karlsruhe (RNK)) (Flesch-Janys et al, 2008) and
were followed up until the end of 2009. The patients were
diagnosed with a histologically confirmed primary invasive or
in situ breast tumour between 1 January 2001 and 30 September
2005 in Hamburg and between 1 August 2002 and 31 July 2005 in
the RNK region and were identified through participating clinics
and the Cancer Registry of Hamburg. Postmenopausal status was
defined by one or more of the following criteria: last menstrual
bleeding at least 12 months before diagnosis, bilateral oopho-
rectomy, or 455 years with unclear menopausal status due to
hysterectomy or hormone use. We included 2668 postmenopausal
patients who completed a food frequency questionnaire (FFQ) and
did not have missing information on cancer before the breast
cancer diagnosis and were not previously diagnosed with cancer
(except for in situ carcinoma, and basal and squamous cell skin
carcinoma).
At recruitment, in-person interviews were performed to collect
information on demographic, anthropometric, socioeconomic, and
lifestyle factors. Moreover, information on suggested and
established breast cancer risk factors and possible prognostic
factors was obtained. Clinical and pathological records were used
to collect information on further prognostic factors.
The study was approved by the ethics committees of the
University of Heidelberg, the University of Hamburg, and the
Medical Board of the State of Rheinland-Pfalz, and conducted in
agreement with the Helsinki declaration. All participants provided
written informed consent at recruitment as well as during
follow-up.
Dietary data
At recruitment, a self-administered validated 176-items FFQ was
completed by the patients, which recorded the nutritional habits
one year before diagnosis. This FFQ was similar to the one used in
the European Prospective into Cancer and Nutrition (EPIC) study,
and nutrient intake (e.g., dietary fibre) was calculated using the
German food composition table Bundeslebensmittelschluessel II.3
(Bundesinstitut für Gesundheitlichen Verbraucherschutz und
Veterinärmedizin) (Bohlscheid-Thomas et al, 1997a, b). For each
food item, the information about portion size and consumption
frequency was used to calculate intakes in grams per day (g day–1).
The two enterolignans, enterolactone and enterodiol, were
estimated from data on incubation with human faeces, in which
the bioavailable enterolignans were calculated per 100 g of ingested
foods (Thompson et al, 1991; Linseisen et al, 2004).
Two lignan-rich food items, sunflower-/pumpkinseeds and
sesame/flaxseeds, were added to the original EPIC-FFQ for this
specific study. Mean daily intake in g day–1 was estimated for each
food item.
A top and bottom energy cutoff of 0.5% was used, as the data
were considered unreliable in extreme ranges of energy intake
(energy range: 425–4577 kcal day–1), resulting in 2653 patients
finally included in the statistical analyses.
Outcome definition
Vital status of all patients was ascertained via local population
registries through the end of 2009, and causes of death were
verified by death certificates and coded based on ICD-10
classifications. The end points of interest were overall survival
(OS) and BCSS. The OS included death from any cause whereas for
BCSS, deaths from breast cancer (coded as ICD-10 C50) were
events of interest and deaths from other causes were censored at
date of occurrence. Women without an event of interest were
censored either at date of last information or end of 2009. Median
follow-up time was calculated as time between diagnosis and the
event of interest or censoring using the reverse Kaplan–Meier
estimation (Schemper and Smith, 1996).
Statistical analysis
Differences in baseline characteristics between deceased and
non-deceased patients were tested using the w2-statistic. The
Kruskal–Wallis test was used to evaluate differences in the levels
of enterolignans and lignan-rich foods between deceased and non-
deceased patients. Spearman’s correlation coefficients were used to
correlate enterolignan intake with other dietary intake variables.
Cox proportional hazards models were used to estimate hazard
ratios (HRs) for OS and BCSS, and their 95% confidence intervals
(CIs) associated with enterolignans and fibre (in quintiles) using
the lowest quintile as reference group. For the assessment of seed
intake and prognosis, non-consumers were used as the reference
category, and were compared with low consumers (intake below
median consumption of the consumers) and high consumers
(intake above and equal to median consumption of the con-
sumers). Total bread (white, brown, and whole-grain), vegetable,
and fruit intake were categorised into tertiles using the lowest
tertile as reference group.
All analyses were stratified by age at diagnosis (in 1-year
categories) and adjusted for the established prognostic factors
tumour size (o2 cm, 2–5 cm, X5 cm, growth into chest wall,
neoadjuvant chemotherapy-treated carcinoma, in situ carcinoma),
nodal status (0, 1–3, 4–9, X10, neoadjuvant chemotherapy-
treated carcinoma, in situ carcinoma), metastasis (yes, no, in situ
carcinoma), grade (1þ 2, 3þ 4, in situ carcinoma, neo-adjuvant
chemotherapy-treated carcinoma), and ER/progesterone receptor
(PR) status (in situ carcinoma, ERþ /PRþ , ERþ /PR or
ER/PRþ , ER/PR, neoadjuvant chemotherapy-treated carci-
noma). Further covariates for the multivariable regression analyses
were determined using a backward elimination procedure based
on Po0.05 in the likelihood ratio test for the covariate or a 410%
change in HR for variable of interest. Thus, the models additionally
included breast cancer detection type (physician-detected by
clinical examination/mammography/ultrasound, self-detected
by palpation/secretion/pain), use of menopausal hormone therapy
at diagnosis (current, never/past), diabetes (yes, no), and
study centre (Hamburg and RNK). Additionally, energy intake
(kcal day–1, continuous) was included as a confounder in the
multivariable regression models. The HER2-neu status, cardio-
vascular diseases, alcohol consumption, smoking habits, occupa-
tional status, type of surgery, phyto-oestrogen supplementation,
adult BMI, physical activity, and further dietary variables
(i.e., vitamin C, fat, carbohydrate, protein, bread, vegetable, and
fruit intake), as well as hormonal, chemo-, and radiotherapy did
not affect the risk estimates in the Cox models. Potential
confounding by fibre was assessed by additional adjustment of
the models of enterolignans for dietary fibre intake (continuous).
Similarly, the model for dietary fibre was additionally adjusted for
enterolactone levels (continuous). Additionally, subgroup analyses
by low and high dietary fibre intake (omedian vs Xmedian) were
performed. Tests for trend of the HRs were performed using
continuous values of the variables.
To assess the functional form of the continuous variables in the
multivariable Cox models, fractional polynomials were applied.
The models with the best –2 log likelihoods were selected (Royston
et al, 1999), resulting in a linear association between the log HR
and exposure variables for OS and BCSS. The test of Grambsch and
Therneau (Grambsch and Therneau, 1994) was used to test the
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proportional hazards assumption and was found to hold for all
analyses.
Effect modification was evaluated using the Q-statistic. Sensi-
tivity analyses were performed by median time between diagnosis
of breast cancer and date of FFQ completion, and by exclusion of
phyto-oestrogen (isoflavone-containing) supplement users. More-
over, a subgroup analysis was conducted for patients with early-
stage breast cancer (stage I–IIIa). Possible effect modification was
assessed using analyses stratified by ER status of the tumour
(positive vs negative), ER/PR status of the tumour (ER- or PR-
positive vs ER-/PR-negative), and menopausal hormone therapy
use at diagnosis (current vs past/never).
For all analyses, two-sided P-values o0.05 were considered
significant. No adjustment for multiple testing was performed
because of the exploratory character of this study. All analyses
were performed using R version 2.9.2 (R Development Core




Selected baseline characteristics of postmenopausal breast cancer
patients are presented in Table 1. Median age at diagnosis of the
patients was 63 years (interquartile range¼ 9 years). Compared
with the non-deceased patients, those who died within the follow-
up period were older, were more likely to have higher adult BMI,
larger tumours, more lymph node involvement, metastases, higher
grade, ER-/PR-negative tumours, diabetes, self-detected tumours,
Table 1 Distribution of sociodemographic variables and prognostic
factors for 2653 postmenopausal breast cancer patients by vital status
Alive Deceased
v2
N % N % P-value
Age at diagnosis (years) o0.01
50–54 170 7.3 22 6.9
55–59 541 23.2 73 22.7
60–65 760 32.6 80 24.9
65–70 622 26.7 88 27.4
70–74 239 10.3 58 18.1
Adult BMI (kgm– 2) o0.01
o18.5 66 2.8 10 3.1
18.5 –25 1757 75.3 212 66.0
25–30 438 18.8 80 24.9
430 71 3.0 19 5.9
Tumour size o0.01
o2 cm 1296 55.6 94 29.3
2–5 cm 715 30.7 141 43.9
X5 cm 61 2.6 22 6.9
Growth into chest wall 36 1.5 28 8.7
In situ 155 6.7 4 1.3
Neoadjuvant chemotherapy 64 2.7 24 7.5
Missing 5 0.2 8 2.5
Nodal status o0.01
0 1507 64.6 121 37.7
1–3 455 19.5 95 29.6
4–9 99 4.3 31 9.7
X10 48 2.1 38 11.8
In situ 155 6.7 4 1.3
Neoadjuvant chemotherapy 64 2.7 24 7.5
Missing 4 0.2 8 2.5
Metastasis o0.01
No 2145 92.0 263 81.9
Yes 23 1.0 48 15.0
In situ 155 6.7 4 1.3
Missing 9 0.4 6 1.9
Grade o0.01
G1+G2 1589 68.1 148 46.1
G3+G4 517 22.2 143 44.6
Table 1 (Continued )
Alive Deceased
v2
N % N % P-value
In situ 155 6.7 4 1.3
Neoadjuvant chemotherapy 64 2.7 24 7.5
Missing 7 0.3 2 0.6
ER/PR status o0.01
ER+/PR+ 1391 59.7 149 46.4
ER+/PR or ER/PR+ 411 17.6 59 18.4
ER/PR 304 13.0 84 26.2
In situ 155 6.7 4 1.3
Neoadjuvant chemotherapy 64 2.7 24 7.5
Missing 7 0.3 1 0.3
HER2-neu status o0.01
Positive 360 15.4 72 22.4
Negative 1528 65.5 195 60.8
In situ 155 6.7 4 1.3
Neoadjuvant chemotherapy 64 2.7 24 7.5
Missing 225 9.7 26 8.1
Breast cancer detection type o0.01
Self-detected 1147 49.2 241 75.1
Physician-detected 1175 50.4 80 24.9
Missing 10 0.4 0 0.0
Menopausal hormone therapy use at diagnosis o0.01
No/past 1151 49.4 226 70.4
Yes 1165 50.0 93 29.0
Missing 16 0.7 2 0.6
Diabetes o0.01
No 2158 92.5 278 86.6
Yes 171 7.3 42 13.1
Missing 3 0.1 1 0.3
Cardiovascular disease o0.01
No 1197 51.3 131 40.8
Yes 1135 48.7 190 59.2
Surgery type o0.01
Breast ablation 263 11.3 76 23.7
Breast conservation 775 33.2 76 23.6
Missing 1294 55.5 169 52.7
Leisure time physical activity (since age 50) 0.38
o28 MET h per week 608 26.1 92 28.7
X28 MET h per week 1701 72.9 229 71.3
Missing 23 1.0 0 0.0
Phyto-oestrogen supplement use 0.16
No 2313 99.2 321 100.0
Yes 19 0.8 0 0.0
Smoking 0.75
Never 1276 54.7 175 54.5
Former 648 27.8 85 26.5
Current 408 17.5 61 19.0
Alcohol (g day – 1) 0.53
0 316 13.6 42 13.1
o19 1719 73.7 231 72.0
X19 296 12.7 48 15.0
Missing 1 0.0 0 0.0
Abbreviations: BMI¼ body mass index; ER¼ oestrogen receptor; HER2-neu¼
human epidermal growth factor receptor 2; PR¼ progesterone receptor;
MET¼metabolic equivalent value.
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and HT use at diagnosis. Deceased patients also had significantly
lower dietary intake of sunflower-/pumpkinseeds, fibre, vegetables,
and fruit, as well as lower exposure to estimated enterolignans
compared with non-deceased patients (all Po0.05; Table 2).
Total estimated enterolignans correlated positively with dietary
sunflower-/pumpkinseed and sesame/flaxseed intake (correlation
of 0.27 and 0.26, respectively), and with fibre intake (correlation of
0.73). Patients with higher enterolignan exposure had higher
energy, carbohydrates, protein, fat, potato, bread, vegetable, and
fruit intake (data not shown).
Prognostic association of enterolignans and
lignan-rich foods
During a median follow-up time of 6.4 years, a total of 321 deaths
occurred, of which 235 were due to breast cancer. Further causes of
death included other cancers (n¼ 41), cardiovascular diseases
(n¼ 22), and other causes (n¼ 23).
Higher estimated levels of enterolactone, enterodiol, and dietary
fibre were associated with significantly reduced overall mortality,
with significantly reduced adjusted HRs for the highest compared
with the lowest quintile (HR¼ 0.60, 95% CI¼ 0.40–0.89,
PTrend¼ 0.02, HR¼ 0.63, 95% CI¼ 0.42–0.95, PTrend¼ 0.02, and
HR¼ 0.52, 95% CI¼ 0.32–0.82, PTrend¼ 0.01, respectively;
Table 3). Multivariable regression modelling using fractional
polynomials confirmed linear associations between exposure
variables and OS. Associations of enterolignans and fibre with
BCSS were similar to that with OS; however, the HRs were not
statistically significant.
Additional adjustment for dietary fibre intake in the assessments
of estimated enterolignans with respect to OS did not substantially
alter the associations; however, they became nonsignificant
(Supplementary Table 1). The association of dietary fibre with
overall mortality also became nonsignificant after adjustment for
enterolactone (Supplementary Table 1). When differentiated
according to median dietary fibre intake, higher levels of both
enterolactone and enterodiol were still significantly associated with
lower overall mortality for the low fibre intake but not high fibre
intake group, although the HRs for the highest quintiles were
nonsignificant (highest quintile for enterolactone HR¼ 0.32, 95%
CI¼ 0.10–1.04, PTrend¼ 0.03 and HR¼ 1.25, 95% CI¼ 0.44–3.58,
PTrend¼ 0.08, respectively, and enterodiol HR¼ 0.48, 95%
CI¼ 0.21–1.07, PTrend¼ 0.01 and HR¼ 1.08, 95% CI¼ 0.38–3.04,
PTrend¼ 0.05, respectively; Table 4).
For the lignan-rich foods, there was no trend in association by
level of consumption although the HRs for low vs no consumption
were significant for sunflower-/pumpkinseeds (0.74, 95%
CI¼ 0.55–0.99) and for sesame/flaxseeds (0.73, 95% CI¼ 0.54–
0.99; Table 5). There was no significant trend with increasing
intake of any lignan-rich food (all PTrend40.1). No association
between lignan-rich foods and BCSS was observed (Table 5).
Sensitivity analysis by median time between diagnosis and
FFQ completion (168 days, interquartile range¼ 414 days) showed
no significant heterogeneity between risk estimates for the
estimated enterolignans, fibre, and lignan-rich foods and OS (all
Pheterogeneity40.05). Exclusion of 19 phyto-oestrogen supplement
users also did not alter the risk estimates for any variable in
association with OS (data not shown).
In 2228 patients with early-stage (I–IIIa) disease, the HRs for
overall mortality associated with estimated enterolignans, fibre,
and lignan-rich foods were similar to that in the total study
population (all Pheterogeneity40.1). The reductions in HR associated
with the highest compared with the lowest quintiles were
stronger for estimated enterolactone (HR¼ 0.49, 95% CI¼ 0.30–
0.80, PTrend¼ 0.02), enterodiol (HR¼ 0.56, 95% CI¼ 0.35–0.91,
PTrend¼ 0.02), and fibre (HR¼ 0.45, 95% CI¼ 0.26–0.80,
PTrend¼ 0.01).
There was no significant heterogeneity in the associations with
estimated enterolignans and fibre by ER status (Supplementary
Table 2), ER/PR status, and menopausal hormone therapy use at
diagnosis (all Pheterogeneity40.1; data not shown).
DISCUSSION
Our data provide first evidence that postmenopausal patients with
higher levels of the estimated enterolignans, enterolactone and
enterodiol, may have a significantly increased OS, which is
independent of ER status of the tumour. Higher dietary fibre
intake was also associated with a significantly better survival after
breast cancer. In addition, the lower mortality associated with
higher enterolignan levels in women with lower than median fibre
intake provides some evidence for an effect of enterolignans, which
is independent of fibre intake.
Table 2 Consumption levels of estimated enterolignans, dietary fibre, and lignan-rich foods by vital status
Item Vital status (N) Mean Median IQR P Kruskal –Wallis
Enterolactone (mg day – 1) Alive (2332) 312.5 279.4 190.5 o0.001
Deceased (321) 280.5 246.7 166.6
Enterodiol (mg day – 1) Alive (2332) 465.3 373.3 296.5 o0.001
Deceased (321) 403.8 325.6 212.8
Fibre (g day – 1) Alive (2332) 20.8 20.0 8.1 0.04
Deceased (321) 20.0 19.6 8.2
Sunflower-/pumpkinseeds (g day – 1) Alive (2332) 3.4 0.2 2.1 0.003
Deceased (321) 2.3 0.2 2.1
Sesame/flaxseeds (g day – 1) Alive (2332) 2.5 0.0 1.4 0.05
Deceased (321) 1.7 0.0 1.4
Bread (g day – 1) Alive (2332) 131.9 123.8 73.5 0.29
Deceased (321) 136.4 130.7 76.5
Vegetables (g day – 1) Alive (2332) 135.8 119.1 72.8 0.05
Deceased (321) 127.1 113.2 73.1
Fruit (g day – 1) Alive (2332) 165.3 130.3 117.2 0.03
Deceased (321) 155.5 106.5 106.9
Abbreviation: IQR¼ interquartile range.
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The estimation of enterolignan – the bioactive forms in the human
body – using the method by Thompson et al (1991), which is based
on in vitro fermentation of various plant foods with human faecal
bacteria, has several strengths. It indirectly accounts for all
enterolignan precursors and covers the long-term exposure to
enterolignans. Nevertheless, the results must be interpreted cautiously
as the estimation does not account for intra- and inter-individual
variation of gut bacteria and metabolism. Also, the estimation is
based on data collected in the early 1990s but, to our knowledge,
there are no other data available to estimate the intestinally produced
amounts of enterolactone and enterodiol, and this approach was also
used by a previous study (Touillaud et al, 2007).
Dietary intake of bread, vegetables, and fruits, which are
important sources of lignans, was not individually associated with
breast cancer prognosis. Intake of seeds, which are rich sources of
lignans (Penalvo et al, 2005), was associated with a nonsignifi-
cantly decreased overall mortality, but there was no significant
dose-response relationship. Of note is that seeds contain other
food constituents, like a-linoleic acids (present in flaxseed), that
have been shown to have anti-carcinogenic and anti-proliferative
properties, which could render a protective effect (Wang et al,
2005; Bozan and Temelli, 2008).
So far, no other study has assessed the association between
estimated enterolignans and breast cancer prognosis. Comparison
of our findings with results on dietary lignan intake may not be
appropriate. Nevertheless, in two smaller studies (each with B800
postmenopausal women) conducted in the United States, higher
dietary lignan intake was associated with lower mortality
after breast cancer in one (McCann et al, 2009) but not in the
other (Fink et al, 2007). Lignan intake was very different in
these studies – one reporting a median intake of 245mg day–1
(McCann et al, 2009) and the other reporting 10 times higher
intake levels (0 to 49mg day–1) (Fink et al, 2007). In line with
our results, a recent Danish study observed a significantly
increased survival with higher plasma enterolactone levels (Olsen
et al, 2011).
Lignans have been found in high amounts in fibre-rich foods
(e.g., cereals, wholegrains), and enterolactone concentrations were
primarily explained by vegetable, rye, and fibre intake in Finnish
men (Nurmi et al, 2010). In our study, the primary sources of
estimated enterolignans were intake of bread (white, brown, and
wholegrain), vegetables, and fruits, which are also rich sources of
fibre. Fibre intake could affect breast cancer risk by several
mechanisms, including stimulation of the intestinal microflora,
reduction of the enterohepatic oestrogen circulation, and thereby
reduction of oestrogen concentrations in the body (Adlercreutz,
2007; Sonestedt and Wirfält, 2010). Additionally, increased fibre
intake was found to be related to lower serum oestradiol levels in
women with breast cancer (Rock et al, 2004).
Table 3 Multivariablea HRs of estimated enterolignans, dietary fibre, and overall and breast cancer-specific mortality of postmenopausal breast
cancer patients
Overall mortality Breast cancer-specific mortality
Q
Median levels
(IQR) (lg day – 1) N Deaths HR (95% CI) PTrend
Breast cancer
deaths HR (95% CI) PTrend
Enterolactone
1 146.0 (41.9) 530 84 1.00 Ref 59 1.00 Ref
2 211.9 (28.6) 531 74 0.87 (0.62–1.22) 54 0.88 (0.59–1.32)
3 274.3 (32.8) 530 53 0.69 (0.48–1.00) 38 0.77 (0.50–1.20)
4 360.7 (50.4) 530 62 0.91 (0.63–1.32) 48 1.18 (0.76–1.82)
5 502.0 (142.5) 532 48 0.60 (0.40–0.89) 0.02 36 0.69 (0.43–1.10) 0.35
Enterodiol
1 186.9 (59.8) 530 76 1.00 Ref 54 1.00 Ref
2 279.8 (39.5) 531 76 0.95 (0.67–1.33) 53 0.92 (0.61–1.39)
3 366.8 (50.2) 530 70 0.97 (0.69–1.37) 53 1.07 (0.72–1.61)
4 499.9 (89.0) 531 53 0.79 (0.54–1.15) 37 0.84 (0.53–1.33)
5 857.5 (368.6) 531 46 0.63 (0.42–0.95) 0.02 38 0.81 (0.51–1.29) 0.40
Fibre
1 13.3 (3.0)b 530 80 1.00 Ref 55 1.00 Ref
2 16.9 (1.5)b 531 62 0.71 (0.50–1.02) 42 0.74 (0.48–1.16)
3 19.9 (1.5)b 531 68 0.68 (0.47–0.97) 56 0.82 (0.54–1.26)
4 23.2 (1.9)b 530 53 0.64 (0.43–0.95) 41 0.71 (0.44–1.14)
5 28.9 (5.7)b 531 53 0.52 (0.32–0.82) 0.01 41 0.64 (0.37–1.11) 0.01
Abbreviations: CI¼ confidence interval; ER¼ oestrogen receptor; HR¼ hazard ratio; IQR¼ interquartile range; PR¼ progesterone receptor; Q¼ quantile. aStratified by age at
diagnosis. Adjusted for tumour size, nodal status, metastasis, grade, ER/PR status, breast cancer detection type, diabetes, menopausal hormone therapy use at diagnosis, study
centre, and energy intake. bIn g day – 1.
Table 4 Multivariablea HRs of enterolignans and overall mortality of
postmenopausal breast cancer patients by dietary fibre intake
Low fibre intakeb High fibre intakeb
Q HR (95% CI) PTrend HR (95% CI) PTrend
Enterolactone
1 1.00 Ref 1.00 Ref
2 0.82 (0.56–1.20) 2.07 (0.67–6.46)
3 0.65 (0.40–1.07) 1.39 (0.48–4.03)
4 0.84 (0.44–1.58) 2.04 (0.71–5.18)
5 0.32 (0.10–1.04) 0.03 1.25 (0.44–3.58) 0.08
Enterodiol
1 1.00 Ref 1.00 Ref
2 0.91 (0.63–1.33) 1.48 (0.50–4.42)
3 0.90 (0.57–1.42) 1.50 (0.54–4.16)
4 0.39 (0.16–0.99) 1.58 (0.57–4.37)
5 0.48 (0.21–1.07) 0.01 1.08 (0.38–3.04) 0.05
Abbreviations: CI¼ confidence interval; ER¼ oestrogen receptor; HR¼ hazard ratio;
PR¼ progesterone receptor; Q¼ quantile. aStratified by age at diagnosis. Adjusted
for tumour size, nodal status, metastasis, grade, ER/PR status, breast cancer detection
type, diabetes, menopausal hormone therapy use at diagnosis, study centre, and
energy intake. bBelow vs equal to or above the median dietary fibre intake.
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To account for potential confounding by fibre, we adjusted the
multivariable regression models for estimated enterolignans and
OS by fibre intake. High levels of estimated enterolignans were no
longer significantly associated with overall mortality, probably
because of their high correlation with fibre, which may have
introduced collinearity in the multivariable models. Also, the
association between dietary fibre and overall survival was no
longer significant after adjustment for enterolactone. Adjustment
for fibre intake was not found to affect the association of lignan
intake with postmenopausal breast cancer risk in a study
conducted in France (Touillaud et al, 2007). However, the
observation of a significant association of estimated enterolignans
with a better prognosis in those with low dietary fibre intake
strengthens the hypothesis that enterolignans may influence the
prognosis of postmenopausal breast cancer independent of fibre
intake. Furthermore, it has been suggested that high lignan intake
might be an indicator of a healthy lifestyle (Sonestedt and Wirfält,
2010). However, adjustment for lifestyle factors including physical
activity, BMI, alcohol, and smoking did not affect the associations
observed for enterolignans.
No significant effect heterogeneity by ER status of the tumours
and menopausal hormone therapy use at diagnosis was observed
for the association of estimated enterolignans and fibre with
overall mortality, which is in line with the results of another study
on dietary lignans and prognosis (Fink et al, 2007). Therefore,
hormone-dependent and -independent mechanisms of action
might be involved in the observed association with enterolignans.
Enterolignans are able to bind to ERs, thereby preventing
endogenous oestrogens from binding and inhibiting tumour
growth stimulation (Adlercreutz and Mazur, 1997). In animal
studies, several hormone-independent mechanisms have been
suggested, such as inhibition of angiogenesis, tumour growth, and
metastasis, as well as stimulation of apoptosis (Power et al, 2006;
Saarinen et al, 2008, 2010). Moreover, an intervention with
flaxseed in postmenopausal breast cancer patients resulted in an
increased apoptosis and a decrease of tumour biological markers
in tumour tissues (Thompson et al, 2005).
The strength of our study was the large population-based
patient sample with complete follow-up and verification of causes
of death using death certificates as well as the consideration of all
relevant prognostic factors. Sensitivity analyses were performed,
which showed that results were not affected by time of diagnosis and
FFQ completion. Additionally, fibre intake, enterolignan levels, and
lignan-rich foods (except for the seeds) were estimated using a
validated dietary questionnaire. Thereby, a broad spectrum of
dietary lignan sources was addressed. The FFQ assessed dietary
habits over the entire 12 months before diagnosis and, thus, captures
the long-term situation of enterolignan exposure.
In the interpretation of our results, we also need to address some
limitations. The assessment of dietary intake may be subject to
measurement errors that are not only due to recall bias but also to
the estimation using food-composition databases, which may not
be complete for the whole range of foods consumed. Dietary
changes after diagnosis, which could have contributed to survival,
were not accounted for in this analysis. Although we collected
comprehensive data and assessed many possible confounding
factors, residual confounding could not be entirely ruled out. Also,
sample size was limited in subgroups and therefore results must be
interpreted cautiously.
In conclusion, we found some evidence for a better prognosis in
postmenopausal breast cancer patients who have high estimated
enterolignan and dietary fibre exposures. The associations of
estimated enterolignans with survival were independent of ER
status of the tumour and may, in part, be independent of dietary
fibre intake. However, further investigations on enterolignans
measured in serum or urine and breast cancer prognosis are
warranted to confirm our results and to disentangle the possible
mechanisms involved.
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Table 5 HRs of phyto-oestrogen-rich foods and overall and breast cancer-specific mortality of postmenopausal breast cancer patients
Food item Survival measure No consumption Low consumptiona High consumptiona PTrend
Sunflower/pumpkinseeds Overall mortality N/deaths (median intake) 1126/157 (0 g day – 1) 747/82 (0.4 g /day – 1) 780/82 (4.5 g day – 1)
Multivariable HR (95% CI)b 1.00 (Ref) 0.74 (0.55–0.99) 0.87 (0.66–1.15) 0.17
BC mortality Multivariable HR (95% CI)b 1.00 (Ref) 0.88 (0.63–1.24) 1.12 (0.79–1.57) 0.35
Sesame/flaxseeds Overall mortality N/deaths (median intake) 1355/182 (0 g day – 1) 591/57 (0.3 g /day – 1) 707/82 (3.6 g /day – 1)
Multivariable HR (95% CI)b 1.00 (Ref) 0.69 (0.50–0.95) 0.90 (0.68–1.19) 0.26
BC mortality Multivariable HR (95% CI)b 1.00 (Ref) 0.75 (0.51–1.09) 1.21 (0.87–1.68) 0.87
Tertile 1 Tertile 2 Tertile 3
Bread Overall mortality N/deaths (median intake) 875/98 (80 g day – 1) 902/118 (125 g day – 1) 876/105 (191 g day – 1)
Multivariable HR (95% CI)b 1.00 (Ref) 1.50 (1.12–2.01) 1.31 (0.93–1.83) 0.07
BC mortality Multivariable HR (95% CI)b 1.00 (Ref) 1.38 (0.98–1.94) 1.10 (0.74–1.63) 0.33
Vegetables Overall mortality N/deaths (median intake) 875/118 (79 g day – 1) 902/100 (118 g day – 1) 876/103 (183 g day – 1)
Multivariable HR (95% CI)b 1.00 (Ref) 0.97 (0.72–1.30) 1.09 (0.80–1.48) 0.56
BC mortality Multivariable HR (95% CI)b 1.00 (Ref) 0.86 (0.61–1.22) 1.01 (0.70–1.46) 0.16
Fruits Overall mortality N/deaths (median intake) 876/122 (79 g day – 1) 902/104 (128 g day – 1) 876/95 (259 g day – 1)
Multivariable HR (95% CI)b 1.00 (Ref) 0.90 (0.68–1.20) 0.84 (0.61–1.16) 0.80
BC mortality Multivariable HR (95% CI)b 1.00 (Ref) 0.90(0.64–1.27) 0.86 (0.59–1.25) 0.82
Abbreviations: BC¼ breast cancer-specific; CI¼ confidence interval; ER¼ oestrogen receptor; HR¼ hazard ratio; PR¼ progesterone receptor. aLow and high consumption
defined by below and above/equal to median consumption of the consumers, respectively. bStratified by age at diagnosis. Adjusted for tumour size, nodal status, metastasis, grade,
ER/PR status, breast cancer detection type, diabetes, menopausal hormone therapy use at diagnosis, study centre, and energy intake. cStratified by age at diagnosis.
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